Unicycive Therapeutics (UNCY)

• Market cap: $67.9M
• 1 day: 5.44%
• 5 days: -5.26%
• 1 month: -1.40%
• 3 months: 50.38%
• 6 months: 61.01%
• Year to date: -17.50%
• 1 year: -21.34%
• 5 years: -88.83%
• 10 years: -88.83%
• Sector: Healthcare
• Industry: Pharmaceutical Preparations

About: Unicycive Therapeutics Inc is a biotechnology company dedicated to developing treatments for certain medical conditions. It is focusing on kidney diseases. The company's lead drug, Renazorb, is a novel phosphate-binding agent being developed for the treatment of hyperphosphatemia. Unicycive's other drug, UNI-494, is a new chemical entity with the issued composition of matter patent protection in late preclinical development for the treatment of acute kidney injury.

Employees: 14

Fund manager confidence

Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)

300% more repeat investments, than reductions

Existing positions increased: 8 | Existing positions reduced: 2

86% more first-time investments, than exits

New positions opened: 13 | Existing positions closed: 7

50% more capital invested

Capital invested by funds: $12.7M [Q2] → $19.1M (+$6.38M) [Q3]

21% more funds holding

Funds holding: 24 [Q2] → 29 (+5) [Q3]

17.65% less ownership

Funds ownership: 67.24% [Q2] → 49.58% (-17.65%) [Q3]

Research analyst outlook

2 Wall Street Analysts provided 1 year price targets over the past 3 months

• Low target: $3 359% upside
• Avg. target: $3.50 435% upside
• High target: $4 512% upside

2 analyst ratings

• positive: 2 100%
• neutral: 0 0%
• negative: 0 0%

HC Wainwright & Co. Ed Arce 42% 1-year accuracy 68 / 161 met price target	512% upside $4	Buy Maintained	8 Jan 2025
Benchmark Bruce Jackson 35% 1-year accuracy 19 / 54 met price target	359% upside $3	Speculative Buy Reiterated	22 Nov 2024